



Angiochem to Present at SNO Annual Meeting

MONTREAL, QC--(Marketwired - November 14, 2016) - Angiochem, a biotechnology company developing peptide drug conjugates uniquely capable of crossing the blood-brain barrier, announced it will make an oral presentation during the 2C Surgery session at the scientific meeting and education day at the Society of Neuro-Oncology (SNO) from November 17-20 in Scottsdale, Arizona. Angiochem's presentation will take place November 18th from 2:25 to 2:30.

"SNO's annual meeting features the latest in clinical research and advancements in neuro-oncology. As such, we are honored to have been chosen to present at this premiere event," said John Huss, Executive Chairman of Angiochem. "We look forward to sharing our insights on ANG1005 for the treatment of patients with recurrent CNS metastasis from breast cancer."

Angiochem is focused on developing ANG1005 for the treatment of Leptomeningeal Carcinomatosis in patients with breast cancer and brain metastases.

Date: November 18th
Time: 2:25-2:30 pm
Presenter: Dr. Santosh Kesari
Abstract #: BMET-28
Title: The novel brain penetrating peptide-drug conjugate ANG1005 shows activity in LC subset of patients with recurrent CNS metastasis from breast cancer

About Angiochem

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address

significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit <http://www.angiochem.com>.

For more information, please contact:

Crystal Quast

Bullseye Corporate

647-529-6364

Quast@BullseyeCorporate.com